Carisbamate acutely suppresses spasms in a rat model of symptomatic infantile spasms
Tomonori Ono
Saul R. Korey Department of Neurology, Laboratory of Developmental Epilepsy, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Search for more papers by this authorSolomon L. Moshé
Saul R. Korey Department of Neurology, Laboratory of Developmental Epilepsy, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Search for more papers by this authorAristea S. Galanopoulou
Saul R. Korey Department of Neurology, Laboratory of Developmental Epilepsy, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Search for more papers by this authorTomonori Ono
Saul R. Korey Department of Neurology, Laboratory of Developmental Epilepsy, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Search for more papers by this authorSolomon L. Moshé
Saul R. Korey Department of Neurology, Laboratory of Developmental Epilepsy, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Search for more papers by this authorAristea S. Galanopoulou
Saul R. Korey Department of Neurology, Laboratory of Developmental Epilepsy, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Search for more papers by this authorSummary
Purpose: Infantile spasms are the signature seizures of West syndrome. The conventional treatments for infantile spasms, such as adrenocorticotropic hormone (ACTH) and vigabatrin, are not always effective, especially in symptomatic infantile spasms (SIS). We tested the efficacy of carisbamate, a novel neurotherapeutic drug, to suppress spasms in the multiple-hit rat model of SIS, and compared it with phenytoin to determine if its effect is via sodium-channel blockade.
Methods: Sprague-Dawley rats received right intracerebral infusions of doxorubicin and lipopolysaccharide at postnatal day 3 (PN3) and intraperitoneal p-chlorophenylalanine at PN5. A single intraperitoneal injection of carisbamate was administered at PN4, after the onset of spasms, at the following doses: 10 mg/kg (CRS-10), 30 mg/kg (CRS-30), and 60 mg/kg (CRS-60), and was compared to vehicle-injected group (VEH). Video-monitoring of PN6-7 CRS-60 or VEH-injected pups was also done.
Key Findings: Carisbamate acutely reduced both behavioral spasms (CRS-30 and CRS-60 groups only) and electroclinical spasms during the first 2–3 postinjection hours, without detectable toxicity or mortality. In contrast, phenytoin (20 or 50 mg/kg) failed to suppress spasms.
Significance: Our findings provide preclinical evidence that carisbamate displays acute anticonvulsive effect on spasms through a sodium channel–independent mechanism. Because spasms in the multiple-hit rat model are refractory to ACTH and transiently sensitive to vigabatrin, carisbamate may constitute a candidate new therapy for SIS, including the ACTH-refractory spasms. Further confirmation with clinical studies is needed.
References
- Allegaert K, Verbesselt R, Naulaers G, van den Anker JN, Rayyan M, Debeer A, de Hoon J. (2008) Developmental pharmacology: neonates are not just small adults. Acta Clin Belg 63: 16–24.
- Andre V, Dube C, Francois J, Leroy C, Rigoulot MA, Roch C, Namer IJ, Nehlig A. (2007) Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model. Epilepsia 48(Suppl. 5): 41–47.
- Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE. (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51: 676–685.
- Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. (2010) Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 92: 89–124.
- Bittigau P, Sifringer M, Genz K, Reith E, Pospischil D, Govindarajalu S, Dzietko M, Pesditschek S, Mai I, Dikranian K, Olney JW, Ikonomidou C. (2002) Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci USA 99: 15089–15094.
- Chien S, Bialer M, Solanki B, Verhaeghe T, Doose DR, Novak G, Yao C. (2006) Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. Epilepsia 47: 1830–1840.
- Chudomelova L, Scantlebury MH, Raffo E, Coppola A, Betancourth D, Galanopoulou AS. (2010) Modeling new therapies for infantile spasms. Epilepsia 51(Suppl. 3): 27–33.
- Cortez MA, Shen L, Wu Y, Aleem IS, Trepanier CH, Sadeghnia HR, Ashraf A, Kanawaty A, Liu CC, Stewart L, Snead OC 3rd. (2009) Infantile spasms and down syndrome: a new animal model. Pediatr Res 65: 499–503.
- Deshpande LS, Nagarkatti N, Sombati S, DeLorenzo RJ. (2008) The novel antiepileptic drug carisbamate (RWJ 333369) is effective in inhibiting spontaneous recurrent seizure discharges and blocking sustained repetitive firing in cultured hippocampal neurons. Epilepsy Res 79: 158–165.
- Eastman CL, Verley DR, Fender JS, Temkin NR, D’Ambrosio R. (2010) ECoG studies of valproate, carbamazepine and halothane in frontal-lobe epilepsy induced by head injury in the rat. Exp Neurol 224: 369–388.
- Eastman CL, Verley DR, Fender JS, Stewart TH, Nov E, Curia G, D’Ambrosio R. (2011) Antiepileptic and antiepileptogenic performance of carisbamate after head injury in the rat: blind and randomized studies. J Pharmacol Exp Ther 336: 779–790.
- Elble RJ, Biondi DM, Ascher S, Wiegand F, Hulihan J. (2010) Carisbamate in essential tremor: brief report of a proof of concept study. Mov Disord 25: 634–638.
- Faught E, Holmes GL, Rosenfeld WE, Novak G, Neto W, Greenspan A, Schmitt J, Yuen E, Reines S, Haas M. (2008) Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures. Neurology 71: 1586–1593.
- Francois J, Boehrer A, Nehlig A. (2008) Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsia 49: 393–399.
- Grabenstatter HL, Dudek FE. (2008) A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 49: 1787–1794.
- Haines ST, Casto DT. (1994) Treatment of infantile spasms. Ann Pharmacother 28: 779–791.
- Kaye CM, Allen A, Perry S, McDonagh M, Davy M, Storm K, Bird N, Dewit O. (2001) The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther 23: 578–584.
- Keck CA, Thompson HJ, Pitkanen A, LeBold DG, Morales DM, Plevy JB, Puri R, Zhao B, Dichter M, McIntosh TK. (2007) The novel antiepileptic agent RWJ-333369-A, but not its analog RWJ-333369, reduces regional cerebral edema without affecting neurobehavioral outcome or cell death following experimental traumatic brain injury. Restor Neurol Neurosci 25: 77–90.
- Klein BD, Smith MD, White HS. (2007) The novel neuromodulator carisbamate delays the acquisition of rat amygdala kindling and maintains acute antiepileptic activity when evaluated in post-kindled rats. Epilepsia 48(Suppl. 6): 367–368.
- Lee CL, Frost JD Jr, Swann JW, Hrachovy RA. (2008) A new animal model of infantile spasms with unprovoked persistent seizures. Epilepsia 49: 298–307.
- Levy R, Ragueneau-Majlessi I, Solanki B, Zannikos P, Yao C, Novak G. (2008) Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly. Epilepsy Res 79: 22–30.
- Liu Y, Yohrling GJ, Wang Y, Hutchinson TL, Brenneman DE, Flores CM, Zhao B. (2009) Carisbamate, a novel neuromodulator, inhibits voltage-gated sodium channels and action potential firing of rat hippocampal neurons. Epilepsy Res 83: 66–72.
- Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O’Callaghan FJ, Verity CM, Osborne JP. (2004) The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 364: 1773–1778.
- Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O’Callaghan FJ, Verity CM, Osborne JP. (2005) The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 4: 712–717.
- Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K, Baram TZ, Duchowny M, Hirtz D, Pellock JM, Shields WD, Shinnar S, Wyllie E, Snead OC 3rd. (2004) Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 62: 1668–1681.
- Mamidi RN, Mannens G, Annaert P, Hendrickx J, Goris I, Bockx M, Janssen CG, Kao M, Kelley MF, Meuldermans W. (2007) Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs. Drug Metab Dispos 35: 566–575.
- Mannens GS, Hendrickx J, Janssen CG, Chien S, Van Hoof B, Verhaeghe T, Kao M, Kelley MF, Goris I, Bockx M, Verreet B, Bialer M, Meuldermans W. (2007) The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans. Drug Metab Dispos 35: 554–565.
- Mares P, Velisek L. (1992) N-methyl-d-aspartate (NMDA)-induced seizures in developing rats. Brain Res Dev Brain Res 65: 185–189.
- Marsh E, Fulp C, Gomez E, Nasrallah I, Minarcik J, Sudi J, Christian SL, Mancini G, Labosky P, Dobyns W, Brooks-Kayal A, Golden JA. (2009) Targeted loss of Arx results in a developmental epilepsy mouse model and recapitulates the human phenotype in heterozygous females. Brain 132(Pt 6): 1563–1576.
- Novak GP, Kelley M, Zannikos P, Klein B. (2007) Carisbamate (RWJ-333369). Neurotherapeutics 4: 106–109.
- Pellock JM, Hrachovy R, Shinnar S, Baram TZ, Bettis D, Dlugos DJ, Gaillard WD, Gibson PA, Holmes GL, Nordli DR, O’Dell C, Shields WD, Trevathan E, Wheless JW. (2010) Infantile spasms: a U.S. consensus report. Epilepsia 51: 2175–2189.
- Price MG, Yoo JW, Burgess DL, Deng F, Hrachovy RA, Frost JD Jr, Noebels JL. (2009) A triplet repeat expansion genetic mouse model of infantile spasms syndrome, Arx(GCG)10+7, with interneuronopathy, spasms in infancy, persistent seizures, and adult cognitive and behavioral impairment. J Neurosci 29: 8752–8763.
- Scantlebury MH, Galanopoulou AS, Chudomelova L, Raffo E, Betancourth D, Moshe SL. (2010) A model of symptomatic infantile spasms syndrome. Neurobiol Dis 37: 604–612.
- Sperling MR, Greenspan A, Cramer JA, Kwan P, Kalviainen R, Halford JJ, Schmitt J, Yuen E, Cook T, Haas M, Novak G. (2010) Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials. Epilepsia 51: 333–343.
- Stafstrom CE. (2009) Infantile spasms: a critical review of emerging animal models. Epilepsy Curr 9: 75–81.
- Trenite DG, French JA, Hirsch E, Macher JP, Meyer BU, Grosse PA, Abou-Khalil BW, Rosenfeld WE, van Gerven J, Novak GP, Parmeggiani L, Schmidt B, Gibson D, Guerrini R. (2007) Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: an exploratory, placebo-controlled study. Epilepsy Res 74: 193–200.
- Velisek L, Jehle K, Asche S, Veliskova J. (2007) Model of infantile spasms induced by N-methyl-d-aspartic acid in prenatally impaired brain. Ann Neurol 61: 109–119.
- Whalley BJ, Stephens GJ, Constanti A. (2009) Investigation of the effects of the novel anticonvulsant compound carisbamate (RWJ-333369) on rat piriform cortical neurones in vitro. Br J Pharmacol 156: 994–1008.
- White HS, Srivastava A, Klein B, Zhao B, Choi YM, Gordon R, Lee SJ. (2006) The novel investigational neuromodulator RWJ 333369 displays a broad-spectrum anticonvulsant profile in rodent seizure and epilepsy models. Epilepsia 47(Suppl. 4): 200–201.
- Zannikos P, Novak G, Yao C, Verhaeghe T, Franc MA, Solanki B, Bialer M. (2009) Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects. Epilepsia 50: 1850–1859.
Citing Literature
